Rethinking Scale: Kurt Mussina on What Site Growth Should Deliver for Sponsors
Kurt Mussina discusses where scale creates real value in clinical research — and why footprint alone is not the measure that matters most.
Scale vs. Integration: Kurt Mussina on What It Takes to Operate Sites as One Platform
Kurt Mussina discusses why site ownership alone does not create an integrated operating model — and what sponsors and CROs should look for beyond site count.
The Real Cost Of Sites Working Without An Enforceable Agreement: Why Your Site’s Quality Of Earnings Is Suspect
In this Clinical Leader article, Kurt Mussina examines the financial and operational risks sites assume when work begins without an enforceable agreement…
Beyond the Numbers: Kurt Mussina on Rethinking How Clinical Research Sites Are Evaluated
Kurt Mussina discusses why traditional measures tell only part of the story when evaluating clinical research site organizations
Why the Governed Hybrid Site Model Creates Strategic Advantage
In the final article of Kurt Mussina’s Clinical Leader series, he focuses on the governed hybrid model and the role of central operating control in building scalable, quality-consistent site platforms.
How Clinical Research Site Operating Models Perform in Practice
In part two of Kurt Mussina’s Clinical Leader series, he examines how different models perform in practice, including freestanding research clinics, embedded private-practice sites, investigator models, site networks, hospital-based models, and pure-play approaches.
Why Operating Model Is the Next Competitive Frontier in Clinical Research Site Strategy
In the first article of a three-part Clinical Leader series, Kurt Mussina introduces operating model as a more meaningful lens for evaluating whether a site organization can turn reach into reliable execution and outlines a taxonomy for understanding the major site operating models in today’s clinical research landscape.
Why Multisite Research Matters White Paper
Discover insights from the new AMRC white paper highlighting how Multisite Clinical Research Corporations (MCRCs) deliver faster start-up, greater consistency, stronger workforce retention, and expanded patient access. Learn why scalable, purpose-built research models are redefining quality in clinical trials.
Amy Henderson on Multi-Site Strategy in International Q&A Feature
Leading Multi-Site Research: Maximizing Efficiency and Reducing Turnover International Clinical Trials, August 2024, pages 95-97. © Samedan Ltd Managing multiple clinical research sites can be challenging, but with the right strategies, it’s entirely achievable. Effective management is key to reducing turnover, streamlining operations, and ensuring smooth research progress across locations. Amy Henderson speaks with International Clinical Trials about how a multi-site research business maximizes efficiency by harnessing challenges as opportunities. Learn best practices for resource allocation, team unification, and technology integration. Discover actionable insights on reducing turnover, standardizing procedures, and creating a motivated, cohesive team. Read Article
San Diego NBC 7 Cytomegalovirus (CMV) Article
Cytomegalovirus (CMV) is making headlines, and it’s behind a majority of US birth defects. The virus spreads through fluids, making it a serious concern for expectant parents. As we uncover more about this alarming situation, it’s crucial to stay informed and take necessary precautions to protect ourselves and our loved ones. Watch or read more in San Diego NBC 7’s “‘It’s spread with fluids’: Little-known virus behind majority of US birth defects” article. Paradigm Clinical Research is currently enrolling participants for a CMV vaccine study. Submit a form to learn more by filling out our join a study form. Knowledge is power, and understanding the risks empowers us to make informed decisions. Let’s share this important article to raise awareness and support clinical research efforts to combat this health challenge. Together, we can strive for a safer and healthier future for generations to come. Because Better Medicines Matter More Than Ever.